Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cenobamate
- Development stage
- Approved
- Lead developer
- SK Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cenobamate is an anticonvulsant medication used to treat partial-onset seizures in adults. It works by inhibiting voltage-gated sodium channels and enhancing GABAergic neurotransmission. Developed by SK Pharmaceuticals, cenobamate is available as oral tablets and can be taken once daily with or without food.
- Brand names
- XcopriOntozry
- Other names
- CenobamatoCenobamatum
02
Targets
GABAA (Gamma-aminobutyric acid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on cenobamate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cenobamate.